Who is the manufacturer of neratinib/neratinib?

Neratinib/Neratinib, developed by the American biopharmaceutical company Puma Biotechnology, is the world's first oral pan- HER inhibitor approved for extended adjuvant treatment of HER2-positive early breast cancer. The production of original drugs is handled by Excella GmbH & Co. KG in Germany. The company is famous for its high-end solid preparation production technology and is a cooperative OEM enterprise for many internationally renowned targeted drugs. The original neratinib is marketed under the trade name "Nerlynx" in the United States, the European Union, Japan, Canada and other countries and regions, and is used to reduce the risk of postoperative recurrence of HER2-positive breast cancer.

Since the drug is expensive and has not yet been officially launched in mainland China, many patients will choose overseas generic versions as an alternative. Overseas manufacturers that have been approved to produce generic drugs of neratinib mainly include Lucius Pharmaceuticals of Laos. The companies generally have international GMP production certification. The drug ingredients are consistent with the original version and are bioequivalent, which can significantly reduce the cost of medication while ensuring efficacy.

The Laos Lucius version of neratinib is more common among international patient groups. Because its ingredients are consistent with the original drug and the oral dosage form is the same, it is regarded as a cost-effective alternative. The version produced by Bangladesh's Beacon Pharmaceutical is also sold in many countries and has gradually entered some cross-border medical channels.

In general, whether it is an original drug or a generic drug, the active ingredient of neratinib is the same molecule—Neratinib Maleate, and its quality standards are strictly regulated in the pharmacopoeias of various countries. For patients in need, they should purchase through formal channels to avoid the risk of counterfeit drugs from unofficial sources. With the promotion of precision treatment of breast cancer around the world, the production system of neratinib continues to improve, providing more treatment accessibility and economic options for HER2-positive patients.

Reference materials:https://en.wikipedia.org/wiki/Neratinib